What is Biliary Tract Cancers?
Biliary Tract Cancers (BTC) constitute epithelial malignancies of the biliary tree and include the following: Gallbladder cancer (GBC) and Cholangiocarcinoma (CCA). The CCA is further divided into intra-hepatic CCA, perihilar (Klatskin’s tumour), and distal CCA. BTC constitutes approximately 3% of all gastrointestinal malignancies and is the most common hepatobiliary cancer after hepatocellular carcinoma.
Biliary Tract Cancers Epidemiology
- As per DelveInsight estimates, total Biliary Tract Cancers incident cases in the 7MM was 70,111 in 2017, and are expected to increase during the study period (2017-2030).
- The higher number of BTC cases were found in the age group 70-79 years with 4,829 in 2017 in the US.
- Among the European 5 countries, Germany had the highest incident population of biliary tract cancers (BTC) with 6,918 cases, followed by Italy, which had the incident population of 6,423 in 2017.
How will Biliary Tract Cancers Market change in the forecast period?
Due to the recent exponential increase in understanding of Biliary Tract Cancers molecular features and the ongoing efforts at developing novel therapies, significant developments in the treatment options for advanced BTC are anticipated in the forecast period.
Biliary Tract Cancers market size in the 7MM was found to be USD 904 Million in 2017. The market size shall increase during the forecast period (2017–2030), owing to the launch of upcoming therapies.
With the continuous efforts in research and development, various companies are developing therapies for Biliary Tract Cancers such as Ivosidenib (Agios Pharmaceuticals), Infigratinib (QED Therapeutics), Melphalan Hydrochloride (Delcath Systems), Futibatinib (Taiho Oncology), Bintrafusp Alfa (Merck Sharp & Dohme), Melphalan Hydrochloride (Delcath Systems), Durvalumab (AstraZeneca), Nanoliposomal Irinotecan (Ipsen), Zanidatamab (BeiGene), Pembrolizumab (Merck Sharp & Dohme), Nab-paclitaxel (Celgene), Fimaporfin (PCI Biotech), Lenvatinib (Eisai), Nivolumab (Bristol-Myers Squibb), Regorafenib (Bayer), Derazantinib (Basilea Pharmaceutica) and others that are expected to enter the Biliary Tract Cancers market by 2030.
For more information on Biliary Tract Cancers market trends, request sample pages here @ https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-market
The Biliary Tract Cancers (BTCs) market report provides current treatment practices, emerging drugs, Biliary Tract Cancers (BTCs) market share of the individual therapies, current and forecasted Biliary Tract Cancers (BTCs) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Biliary Tract Cancers (BTCs) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market. The Biliary Tract Cancers (BTCs) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Biliary Tract Cancers (BTCs) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a thorough detail of Biliary Tract Cancers (BTCs) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
For more information on Biliary Tract Cancers market trends, request sample pages here @ https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-market
Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/